Compare RAMP & IMNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RAMP | IMNM |
|---|---|---|
| Founded | 2018 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.5B |
| IPO Year | 1994 | 2020 |
| Metric | RAMP | IMNM |
|---|---|---|
| Price | $37.52 | $21.56 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 10 |
| Target Price | ★ $35.60 | $32.80 |
| AVG Volume (30 Days) | ★ 1.1M | 975.9K |
| Earning Date | 05-20-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 22500.00 | 51.40 |
| EPS | ★ 0.28 | N/A |
| Revenue | ★ $812,940,000.00 | $6,941,000.00 |
| Revenue This Year | $11.18 | N/A |
| Revenue Next Year | $9.09 | $1,127.34 |
| P/E Ratio | $133.86 | ★ N/A |
| Revenue Growth | ★ 9.03 | N/A |
| 52 Week Low | $21.71 | $11.09 |
| 52 Week High | $38.23 | $30.06 |
| Indicator | RAMP | IMNM |
|---|---|---|
| Relative Strength Index (RSI) | 43.09 | 31.93 |
| Support Level | $37.29 | $19.39 |
| Resistance Level | $37.92 | $23.25 |
| Average True Range (ATR) | 0.16 | 1.19 |
| MACD | -0.03 | -0.40 |
| Stochastic Oscillator | 13.16 | 5.33 |
LiveRamp Holdings Inc is a technology company that empowers marketers and media owners to deliver and measure marketing performance everywhere it matters. Its data collaboration network seamlessly unites data across advertisers, ad tech platforms, publishers, data providers, and commerce media networks, unlocking insights that deliver transformational consumer experiences and drive measurable business outcomes. The group's platform is engineered for AI agent accessibility, facilitating autonomous data collaboration between the specialized AI agents utilized by customers and partners and the networked platform. It generates the geographic revenue from the United States, followed by Europe, Asia-Pacific ("APAC"), and Other.
Immunome Inc is a biotechnology company focused on developing first-in-class targeted oncology therapies. The company specializes in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics. Its pipeline includes varegacestat, an investigational oral gamma secretase inhibitor that reported positive topline results in the Phase 3 RINGSIDE trial for progressing desmoid tumors; IM-1021, a ROR1 antibody-drug conjugate under evaluation in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand therapy with IND clearance and a planned Phase 1 trial. The company is also advancing preclinical solid tumor ADCs, including IM-1617, IM-1340, and IM-1335.